Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co's Dr Daniel Pascheles joins Molekule Consulting

He becomes the biopharma services provider’s CEO

Molekule Consulting Dr Daniel PaschelesMiami, US-based Molekule Consulting has appointed Dr Daniel Pascheles as its new chief executive officer.

Dr Daniel Pascheles joins from Merck & Co, where he served as vice president and head of global competitive intelligence for the last 12 years.

While at Merck, Dr Pascheles provided strategy development, target and candidate identification for the firm's licensing, business development and M&A activities, alongside leading the CI department.

Prior to this, Dr Pascheles worked at Aventis Pharmaceuticals - as well as its predecessor companies - for over 14 years, latterly as its vice president.

His previous roles include head of global competitive intelligence, global marketing director, general manager of Switzerland and European head of sales, marketing administration and strategic planning.

David Alderman, Molekule Consulting's founder and president, said: “Dr Pascheles is one of the most experienced, ethical and well-respected CI professionals in our industry; he is a global leader who brings expertise and exceptional vision to build our growing company.”

6th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics